Agree with what you said. IL-2 therapy (in Melanoma at least) on its own I believe is like 9-10 cycles (though most patients can't tolerate more than a couple even in ICU environment). I believe its one of the best (though still low) chances for a cure just few can get through enough cycles.
There also wasn't (in the abstract) a break down of patients from those newer to therapy vs. reported earlier to know the ORR of the same patients.
The other angle people are overlooking is 214/Nivo is not the only route forward. They are pursuing multiple combo's though most are earlier stage (there are a couple of posters at ASCO) it seems the new deal will have triplets (214, Nivo, Yervoy).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.